Multiple Sclerosis

Researchers have discovered a new subtype of MS, providing a better understanding of the nature of the disease.

Discontinuing disease-modifying therapies is common among patients with MS but can increase the risk of progression or relapse.

Discontinuing disease-modifying therapies is common among patients with MS but can increase the risk of progression or relapse.

The US Food and Drug Administration has granted approval to a new dose of a drug used to treat relapsing forms of multiple sclerosis.

In a recent study, researchers investigated the effects of high levels of fat and vegetable intake on MS relapse rates in children.

The FDA has approved a generic option for the treatment of patients with relapsing forms of multiple sclerosis. For details, including dosage and common adverse effects, read more.

In a recent study, researchers investigated the effects of chronic comorbidities on time to diagnosis and mortality in patients with multiple sclerosis. For details, including which types of comorbidity...

In a recent study, researchers sought to determine whether and to what extent low vitamin D levels are associated with the risk for developing multiple sclerosis.

Neurodegenerative disease processes can start before clinical manifestation of the disease, but the prodrome of MS is not well defined.

The FDA approved Ocrevus for the treatment of relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adult patients.